NCT07115173View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

December 31, 2027

Conditions
Helicobacter Infection
Interventions
DRUG

This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.

This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.

All Listed Sponsors
lead

Samsung Medical Center

OTHER